# Efficacy and Safety Study of Thymosin Beta 4 in Patients With Acute Myocardial Infarction

> **NCT05984134** · PHASE2 · COMPLETED · sponsor: **Beijing Northland Biotech. Co., Ltd.** · enrollment: 90 (actual)

## Conditions studied

- Acute Myocardial Infarction

## Interventions

- **DRUG:** NL005 Middle Dose
- **DRUG:** NL005 High Dose
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05984134
- **Lead sponsor:** Beijing Northland Biotech. Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-07-15
- **Primary completion:** 2023-05-26
- **Final completion:** 2023-05-29
- **Target enrollment:** 90 (ACTUAL)
- **Last updated:** 2024-06-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05984134

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05984134, "Efficacy and Safety Study of Thymosin Beta 4 in Patients With Acute Myocardial Infarction". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05984134. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*